Eledon Pharmaceuticals, Inc. (ELDN)
NASDAQ: ELDN · Real-Time Price · USD
3.580
+0.040 (1.13%)
At close: Aug 17, 2026, 4:00 PM EDT
3.550
-0.030 (-0.84%)
After-hours: Aug 17, 2026, 7:34 PM EDT
Eledon Pharmaceuticals Employees
Eledon Pharmaceuticals had 33 employees as of December 31, 2025. The number of employees increased by 2 or 6.45% compared to the previous year.
Employees
33
Change (1Y)
2
Growth (1Y)
6.45%
Revenue / Employee
n/a
Profits / Employee
-$2,986,697
Market Cap
291.20M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 33 | 2 | 6.45% | 33 | 0 |
| Dec 31, 2024 | 31 | 11 | 55.00% | 31 | 0 |
| Dec 31, 2023 | 20 | 3 | 17.65% | 20 | 0 |
| Dec 31, 2022 | 17 | 5 | 41.67% | 17 | 0 |
| Dec 31, 2021 | 12 | 2 | 20.00% | 12 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Bicycle Therapeutics | 288 |
| Fate Therapeutics | 161 |
| Neumora Therapeutics | 92 |
| InflaRx | 65 |
| Sionna Therapeutics | 59 |
| Surrozen | 44 |
| Anavex Life Sciences | 34 |
| Sol-Gel Technologies | 28 |
ELDN News
- 1 day ago - Eledon Pharmaceuticals reports Q2 EPS (27c), consensus (15c) - TheFly
- 4 days ago - Eledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Business Highlights - GlobeNewsWire
- 4 days ago - Eledon Pharmaceuticals Earnings release: Q2 2026 - Filings
- 4 days ago - Eledon Pharmaceuticals Quarterly report: Q2 2026 - Filings
- 4 days ago - Eledon Pharmaceuticals Slides: Corporate presentation - Filings
- 27 days ago - Eledon Pharmaceuticals initiated with a Buy at Rodman & Renshaw - TheFly
- 7 weeks ago - Natera, Eledon announce strategic partnership - TheFly
- 7 weeks ago - Natera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trial - Business Wire